Sientra Stock Sinks on 4Q Whiff, Downgrade

SIEN is on track for its worst day since 2015

by Patrick Martin

Published on Mar 13, 2019 at 10:23 AM

The shares of Sientra Inc (NASDAQ:SIEN) are down 22.5% to trade at $8.82, one of the worst stocks on the Nasdaq this morning, after the company reported a fourth-quarter loss of 86 cents per share, steeper than the 68 cents per-share loss analysts were expecting. In response, William Blair downgraded the silicone implants producer to "market perform," while SVB Leerink and Dougherty trimmed their price targets to $18 and $27, respectively.

SIEN is on track for its worst single-session loss since September 2015, and has been stuck in a channel of lower highs and lows since its Sept. 10 peak near $27. More recently, the $10 level had served as a short-term floor for the shares, with their 50-day moving average containing breakout attempts above. Earlier though, the equity tapped its March 26 bottom of $8.79. 

The equity could be pressured lower by more bear notes. While all seven brokerages in coverage of SIEN rated it a "buy" or better at last night's close, its consensus 12-month price target of $21.43 is a 142.4% premium to the security's current perch. 

Short sellers are likely cheering today's collapse. While short interest fell 12.6% in the most recent reporting period, the 2.3 million shares still sold short represents a healthy 11.9% of SIEN's total available float, and 3.4 times the average daily trading volume. However, these bears are sidelined at the moment, with the stock on the short-sale restricted list.

a schaeffer's exclusive


Heat up your summer trading with this FREE insider report!



NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories

This Might Be the Ultimate Cannabis Stock
This innovative company could help investors see some major upside.
3 Drug Stocks Seeing Unusual Options Trading Today
The FDA approved Sesen's request to move manufacturing for its bladder cancer drug
BofA-Merrill Lynch: Buy This Shoe Stock Before Earnings
The brokerage firm thinks the retailer can rally another 26%
This Might Be the Ultimate Cannabis Stock
This innovative company could help investors see some major upside.